| Bioactivity | NG-nitro-L-arginine (Nω-nitro-L-arginine) is a NO Synthase inhibitor, with Kis of 0.61 μM (nNOS), 4.28 μM (iNOS), 0.72 μM (eNOS) respectively. NG-nitro-L-arginine inhibits endothelium-derived relaxing factor (EDRF) formation and release. NG-nitro-L-arginine inhibits portal-systemic shunting in portal-hypertensive rats, and increases blood pressure[1][2][3][4]. | ||||||
| Target | Kis: 0.61 μM (nNOS), 4.28 μM (iNOS), 0.72 μM (eNOS) | ||||||
| CAS | 2149-70-4 | ||||||
| Formula | C6H13N5O4 | ||||||
| Molar Mass | 219.20 | ||||||
| Appearance | 固体 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Store at room temperature 3 years
|
||||||
| Reference | [1]. Seo J, et al. Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. J Med Chem. 2007 May 3;50(9):2089-99. [2]. Ishii K, et al. N omega-nitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol. 1990 Feb 6;176(2):219-23. [3]. Lee FY, et al. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 1993 Nov;105(5):1464-70. [4]. Molnár M, Hertelendy F. N omega-nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am J Obstet Gynecol. 1992 May;166(5):1560-7. |
NG-nitro-L-arginine
CAS: 2149-70-4 F: C6H13N5O4 W: 219.20
NG-nitro-L-arginine (Nω-nitro-L-arginine) is a NO Synthase inhibitor, with Kis of 0.61 μM (nNOS), 4.28 μM (iNOS), 0.7
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.